List view / Grid view

Sandoz

Filter the results

 

news

Sandoz proposed biosimilars recommended for EU approval

25 April 2017 | By Niamh Marriott, Junior Editor

The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.